Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised Phase II Trial of Olaparib, Chemotherapy or Olaparib and Cediranib in Patients With Platinum-resistant Ovarian Cancer

NCT03117933 is registered in ClinicalTrials.gov with University of Oxford as lead sponsor.

NCT NCT03117933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03117933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised Phase II Trial of Olaparib, Chemotherapy or Olaparib and Cediranib in Patients With Platinum-resistant Ovarian Cancer
Lead sponsor
University of Oxford
Phase
Phase 2
Overall status
Completed
Start date
March 9, 2017
Completion date
December 31, 2023
Enrollment
139 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer